BioCryst Pharmaceuticals (BCRX) Technical Analysis

As of 2026-07-22, BCRX last traded at 9.51 USD (+0.96% on the day) and is in a uptrend on the daily timeframe — price above rising 50-DMA, 50-DMA above 200-DMA. Nearest levels: 8.905 USD support below, 9.82 USD resistance above. 14-day RSI is 48.3 (neutral).

Last updated 2026-07-22 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ

Is BCRX in an uptrend or downtrend?

BioCryst Pharmaceuticals is in a uptrend — price above rising 50-DMA, 50-DMA above 200-DMA.

Last close9.51 USD (+0.96%)
20-day average9.891 USD
50-day average9.214 USD
200-day average8.154 USD

Key support and resistance levels for BCRX

Derived from swing pivots over the last 200 sessions:

LevelTypeStrengthTouches
9.82 USDResistanceMinor1
9.98 USDResistanceMinor1
10.32 USDResistanceMinor1
LevelTypeStrengthTouches
8.905 USDSupportModerate2
8.56 USDSupportMinor1
8.31 USDSupportMinor1

BCRX 52-week range, momentum and volatility

52-week high11.22 USD (15.2% below)
52-week low6 USD (58.5% above)
14-day RSI48.3 (Neutral)
14-day ATR0.503 USD (5.29% of price, High volatility)

Related research pages

Frequently asked questions

Is BioCryst Pharmaceuticals (BCRX) in an uptrend or downtrend?

As of 2026-07-22, BCRX is in a uptrend on the daily timeframe — price above rising 50-DMA, 50-DMA above 200-DMA. Last close 9.51 USD vs 50-day average 9.214 USD and 200-day average 8.154 USD.

What are the key support and resistance levels for BCRX?

Nearest support is around 8.905 USD (moderate, 2 touches). Nearest resistance is around 9.82 USD (minor). Levels are derived from swing pivots over the last ~200 sessions.

What is BCRX's 52-week high and low?

Over the last 52 weeks, BCRX traded between 6 USD and 11.22 USD. It is currently 15.2% below its 52-week high.

Is BCRX overbought or oversold?

The 14-day RSI is 48.3 — in a neutral 30–70 range. Momentum reads as neutral.

How volatile is BCRX?

Its 14-day Average True Range is 0.503 (5.29% of price) — high volatility relative to price.